KFU. Card publication. Musashi 2 (MSI2) expression as an independent prognostic biomarker in non-small cell lung cancer (NSCLC)

KAZAN
FEDERAL UNIVERSITY

- RUS
- 中文
- ES

MUSASHI 2 (MSI2) EXPRESSION AS AN INDEPENDENT PROGNOSTIC BIOMARKER IN NON-SMALL CELL LUNG CANCER (NSCLC)

Form of presentation

Conference proceedings in international journals and collections

Year of publication

2020

��

��

Authors, employees of KFU

Bumber Yanis Alekseevich, author

Deneka Aleksandr Yaroslavovich, author

Topchu Yuliya Alekseevna, author

Yugay Veronika Nikolaevna, author

Other authors

Ratner Ekaterina Yurevna, author

Authors, postgraduates KFU

Mazitova Aleksandra Maratovna, postgraduate kfu

Bibliographic description in the original language

Deneka A. Musashi 2 (MSI2) expression as an independent prognostic biomarker in non-small cell lung cancer (NSCLC)/ A. Deneka, L.Kharin, N. S. Karnaukhov, M.Voloshin, T.G. Ayrapetova, E. Ratner, A.Sabirov, Y.Topchu, A. Mazitova, Z.Abramova, V.Yugai, E.M. Frantsiyants, O. I. Kit, Y. Boumber/ 2020 ASCO Annual Meeting- ASCO's 15th Annual Report on Progress Against Cancer // Journal of Clinical Oncology. - 2020.- V 38, Is. 15_suppl e21583-e21583

Annotation

Journal of Clinical Oncology

Keywords

Musashi 2, biomarker, non-small cell lung cancer

The name of the journal

Journal of Clinical Oncology

URL

https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.e21583?af=R

Please use this ID to quote from or refer to the card

https://repository.kpfu.ru/eng/?p_id=248013&p_lang=2

Full metadata record

Field DC	Value	Language
dc.contributor.author	Bumber Yanis Alekseevich	ru_RU
dc.contributor.author	Deneka Aleksandr Yaroslavovich	ru_RU
dc.contributor.author	Topchu Yuliya Alekseevna	ru_RU
dc.contributor.author	Yugay Veronika Nikolaevna	ru_RU
dc.contributor.author	Ratner Ekaterina Yurevna	ru_RU
dc.contributor.author	Mazitova Aleksandra Maratovna	ru_RU
dc.date.accessioned	2020-01-01T00:00:00Z	ru_RU
dc.date.available	2020-01-01T00:00:00Z	ru_RU
dc.date.issued	2020	ru_RU
dc.identifier.citation	Deneka A. Musashi 2 (MSI2) expression as an independent prognostic biomarker in non-small cell lung cancer (NSCLC)/ A. Deneka, L.Kharin, N. S. Karnaukhov, M.Voloshin, T.G. Ayrapetova, E. Ratner, A.Sabirov, Y.Topchu, A. Mazitova, Z.Abramova, V.Yugai, E.M. Frantsiyants, O. I. Kit, Y. Boumber/ 2020 ASCO Annual Meeting- ASCO's 15th Annual Report on Progress Against Cancer // Journal of Clinical Oncology. - 2020.- V 38, Is. 15_suppl e21583-e21583	ru_RU
dc.identifier.uri	https://repository.kpfu.ru/eng/?p_id=248013&p_lang=2	ru_RU
dc.description.abstract	Journal of Clinical Oncology	ru_RU
dc.description.abstract	e21583 Background: Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related death in the world, and metastasis is the most common cause of death in lung cancer patients. Musashi-2 (MSI2) is a member of RNA-binding protein family and regulates mRNA translation of numerous intracellular targets, and influences multiple biological processes, including maintenance of stem cell identity. Previously we reported that MSI2 is upregulated in the metastasis-competent NSCLC murine and human cell lines, drives NSCLC metastasis, and is progressively elevated in lung cancer patient samples. This study assessed MSI2 as potential clinical biomarker in NSCLC. Methods: The current study included 40 patients with NSCLC, of whom 15 presented with stage II and III respectively (37,5% each), and 10 patients (25%) had stage IV. All patients received treatment in accordance with the NCCN guidelines, and did not participate in clinical trials. All patient samples were obtained before treatment started. We used immunohistochemical (IHC) approach to measure MSI2 expression on the protein level in matching specimens of normal versus tumor tissues, and primary tumor vs. metastasis, followed by correlative analysis in relation to clinical outcomes. In parallel, clinical correlative analysis of MSI2 mRNA expression was performed in silico using publicly available datasets (TCGA/ICGC) as of January 2020. Results: MSI2 protein expression in patient samples was significantly elevated in NSCLC primary tumors and metastatic sites versus normal tissue (p = 0.03). MSI2 elevated expression positively correlated with a decreased progression free survival (PFS) (p = 0.026) at all stages and overall survival at stage IV (p = 0.013). Elevated MSI2 expression on RNA level was observed in primary tumor versus normal tissue samples in TCGA (p < 0.0001), and positively correlated with decreased OS (p = 0.028). No correlation was observed between MSI2 expression and age, sex, smoking, and treatment type. Conclusions: Elevated MSI2 expression in primary NSCLC tumors is associated with poor prognosis and can be used as a novel potential prognostic biomarker in NSCLC patients. Future studies in an extended patient cohort are strongly warranted. ? 2020 American Society of Clinical Oncology	ru_RU
dc.language.iso	ru	ru_RU
dc.subject	Musashi 2	ru_RU
dc.subject	biomarker	ru_RU
dc.subject	non-small cell lung cancer	ru_RU
dc.title	Musashi 2 (MSI2) expression as an independent prognostic biomarker in non-small cell lung cancer (NSCLC)	ru_RU
dc.type	Conference proceedings in international journals and collections	ru_RU